Switch theme
Sign up to access all valuation multiples
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
1986
509
LTM Revenue $207M
LTM EBITDA $38.0M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pharma Mar has a last 12-month revenue (LTM) of $207M and a last 12-month EBITDA of $38.0M.
In the most recent fiscal year, Pharma Mar achieved revenue of $196M and an EBITDA of $23.8M.
Pharma Mar expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pharma Mar valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $207M | XXX | $196M | XXX | XXX | XXX |
| Gross Profit | $198M | XXX | $187M | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | 95% | XXX | XXX | XXX |
| EBITDA | $38.0M | XXX | $23.8M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 12% | XXX | XXX | XXX |
| EBIT | $26.0M | XXX | $7.1M | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $43.6M | XXX | $29.3M | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Pharma Mar's stock price is EUR 85 (or $95).
Pharma Mar has current market cap of EUR 1.5B (or $1.6B), and EV of EUR 1.4B (or $1.5B).
See Pharma Mar trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $1.6B | XXX | XXX | XXX | XXX | $2.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Pharma Mar has market cap of $1.6B and EV of $1.5B.
Pharma Mar's trades at 7.9x EV/Revenue multiple, and 64.9x EV/EBITDA.
Equity research analysts estimate Pharma Mar's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pharma Mar has a P/E ratio of 37.8x.
See valuation multiples for Pharma Mar and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 7.5x | XXX | 7.9x | XXX | XXX | XXX |
| EV/EBITDA | 40.7x | XXX | 64.9x | XXX | XXX | XXX |
| EV/EBIT | 59.6x | XXX | 218.7x | XXX | XXX | XXX |
| EV/Gross Profit | 7.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 37.8x | XXX | 56.1x | XXX | XXX | XXX |
| EV/FCF | 115.3x | XXX | -145.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPharma Mar's last 12 month revenue growth is 20%
Pharma Mar's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.
Pharma Mar's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pharma Mar's rule of X is 67% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pharma Mar and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | 115% | XXX | 273% | XXX | XXX | XXX |
| Rule of 40 | 22% | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 67% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 59% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 92% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pharma Mar acquired XXX companies to date.
Last acquisition by Pharma Mar was XXXXXXXX, XXXXX XXXXX XXXXXX . Pharma Mar acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Pharma Mar founded? | Pharma Mar was founded in 1986. |
| Where is Pharma Mar headquartered? | Pharma Mar is headquartered in Spain. |
| How many employees does Pharma Mar have? | As of today, Pharma Mar has 509 employees. |
| Is Pharma Mar publicy listed? | Yes, Pharma Mar is a public company listed on MAD. |
| What is the stock symbol of Pharma Mar? | Pharma Mar trades under PHM ticker. |
| When did Pharma Mar go public? | Pharma Mar went public in 2000. |
| Who are competitors of Pharma Mar? | Similar companies to Pharma Mar include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Pharma Mar? | Pharma Mar's current market cap is $1.6B |
| What is the current revenue of Pharma Mar? | Pharma Mar's last 12 months revenue is $207M. |
| What is the current revenue growth of Pharma Mar? | Pharma Mar revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Pharma Mar? | Current revenue multiple of Pharma Mar is 7.5x. |
| Is Pharma Mar profitable? | Yes, Pharma Mar is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Pharma Mar? | Pharma Mar's last 12 months EBITDA is $38.0M. |
| What is Pharma Mar's EBITDA margin? | Pharma Mar's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Pharma Mar? | Current EBITDA multiple of Pharma Mar is 40.7x. |
| What is the current FCF of Pharma Mar? | Pharma Mar's last 12 months FCF is $13.4M. |
| What is Pharma Mar's FCF margin? | Pharma Mar's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Pharma Mar? | Current FCF multiple of Pharma Mar is 115.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
